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Hydrazine based derivatization reagents have been used to detect the presence of the carbonyl containing 
glucocorticoid fluticasone proprionate in rat lung tissue by MALDI-MSI. Such reagents also act as a matrix 
for analysis by MALDI-MS and have been termed "reactive matrices". Cryosections of rat lung tissue (12 m) 
spotted with a range of concentrations of fluticasone proprionate, were derivatized in situ with 2,4-
dinitrophenylhydrazine (DNPH) and 4-Dimethylamino-6-(4-methoxy-1-naphthyl)-1, 3, 5-triazine-2-hydrazine 
(DMNTH) by the use of an acoustic reagent spotter. It has been demonstrated that DMNTH gave superior 
results compared to DNPH and that analysis of samples immediately after application of DMNTH  resulted in 
the detection of the protonated hydrazone derivative ([MD+H]
+
) of fluticasone propionate at a concentration of 
500 ng/µL. It has been further shown that a prolonged reaction time (~48 hours) improves the detection limit 
of the protonated hydrazone derivative to 50 ng/µL and that improvements in sensitivity and limits of 
detection are obtained when a conventional MALDI matrix CHCA is employed in conjunction with the 
DNPH/ DMNTH reactive matrix. 
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1. Introduction 
Corticosteroids are the mainstay of asthma management and are used to treat the inflammatory response 
associated with the disease. Depending on the severity of asthma the amount of fluticasone propionate a 
patient must inhale can range from 150-1000 µg two times per day (www.medicines.org.uk). The ability to 
monitor their distribution in the lungs would be useful to assess the efficiency of drug delivery. Matrix-
assisted laser desorption/ionization-mass spectrometry imaging (MALDI-MSI) provides a label free method to 
monitor the distribution of pharmaceutical compounds in biological tissue sections. As part of a project to 
study the distribution of corticosteroids in dosed rat lung tissue sections by MALDI-MSI, methodologies for 
on-tissue derivatization have been studied. Corticosteroids contain multiple carbonyl functionalities which are 
not easily protonated/ de-protonated under mass spectrometry conditions, due to their low ionisation 
efficiencies. Derivatization has been proposed as a solution to this problem by introduction of groups with 
fixed charges or with high proton affinity. An additional benefit of the use of derivatization in “soft” 
ionisation mass spectrometry techniques such as MALDI-MS is that it can help prevent matrix-related ion 
suppression and isobaric overlay between matrix and analyte peaks by the introduction of groups with fixed 
charges or easily ionisable groups [1]. 
The most common derivatization reactions of carbonyl compounds reported for analysis by “soft” ionisation 
mass spectrometry methods are based on the formation of oximes and hydrazones [1]. Other published 
methods involve the formation of Schiff’s bases, semicarbazones and thiosemicarbazones [2]. Whilst there are 
many derivatization reagents available, there is not, in reality, a preferred universal reagent. Thus the choice is 
usually determined by experimentation. There are several requirements to consider when choosing the ideal 
derivatization reagent for use: 1) the reagent should be pre-charged or include a group having high proton 
affinity, 2) it must contain a suitable reactive group and 3) preferably it should be commercially available or 
synthesised using inexpensive reagents [1, 3]. Careful consideration should be made when selecting the 
derivatization reagent for example smaller reagents are suited for sterically hindered functional groups, the 
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addition of a larger reagent can have the desired effect of moving the mass of the derivative into the higher 
mass region of the mass spectrum [2]. 
2,4-Dinitrophenylhydrazine (DNPH) is the most commonly used hydrazine based reagent for derivatizing the 
carbonyl functionalities of aldehydes and ketones for liquid chromatographic separation followed by UV/Vis 
or fluorescence detection [4]. DNPH is characterised as a "reactive matrix" as it not only derivatizes the 
carbonyl containing compounds but also assists in desorption and ionisation in MALDI-MS [4]. DNPH has 
been used previously for the derivatization and analysis of corticosteroids by MALDI-MS [5]. The analysis of 
the derivatized corticosteroids showed a radical cation ([M]
+•
) which is formed via charge transfer reactions, 
as well as the protonated derivatized molecule ([MD+H]
+
) [5]. This effect has been studied here.  
DNPH has also been used for the derivatization of phospholipids and their related oxidation products for 
analysis by MALDI-MS [6]. DNPH or a mixture of DNPH and CHCA has been utilised for the direct analysis 
of formalin-fixed paraffin embedded (FFPE) tissue samples, that had been stored for less than 1 year. DNPH 
was used to neutralise any residual formalin molecules in order to improve the signal of peptides greater than 
5000 kDa and adducts corresponding to (protein-N=CH2) were suppressed [7]. Recently it has been shown 
that digestion of spermatozoa samples with phospholipase A2 followed by derivatization with DNPH, can be 
used for the identification of plasmalogens in complex lipid mixtures [8]. 
4-Dimethylamino-6-(4-methoxy-1-naphthyl)-1, 3, 5-triazine-2-hydrazine (DMNTH) is a “tailor-made” 
derivatization reagent that combines selective reactive functionality, stability and good spectroscopic 
properties in one compound [9]. This reagent was developed by the Karst group at the University of Münster, 
Germany. It is synthesised by substitution reactions of cyanuric chloride, which acts as a base molecule to 
couple functional groups that have specific roles in the detection, reactivity and polarity of the derivatization 
agent. There are several reports on the use of DMNTH as a derivatization reagent. Examples are the 
derivatization of carbonyl containing compounds followed by chromatographic separation and detection by 
atmospheric pressure chemical ionisation (APCI) mass spectrometry and in water samples [10, 11]. The 
optimised parameters necessary for the separation of DMNTH derivatized carbonyl compounds by reversed 
phase capillary electrochromatography (CEC) have been described [12]. 
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Test tubes coated with DMNTH have been used for the determination of aldehydes in air samples followed by 
chromatographic separation and detection by UV-Vis and fluorescence spectroscopy, the results were found to 
be comparable to the established method using the derivatization reagent DNPH [13]. The most recent 
application of DMNTH reported [9], is for the derivatization and analysis of a range of carbonyl containing 
compounds by laser desorption ionisation-mass spectrometry (LDI-MS). 
The hydrazine based reagents DNPH and DMNTH have been employed for the derivatization of a range of 
glucocorticoids both in-solution and on-tissue to form their respective hydrazones and improve their mass 
spectral ionisation efficiency and detection. In the work reported here fluticasone propionate has been selected 





All animal studies were ethically reviewed and carried out in accordance with Animals (Scientific Procedures) 
Act 1986 and the GSK Policy on the Care, Welfare and Treatment of Laboratory Animals. 
 
2.2. Materials 
The reagents α-cyano-4-hydroxycinnamic acid (CHCA), fluticasone propionate (C25H31F3O5S, MW 500.57), 
beclomethasone dipropionate (C28H37ClO7, MW 520.22), budesonide (C25H34O6, MW 430.23), trifluoroacetic 
acid (TFA) and ALUGRAM1 SIL G/UV254 precoated aluminum sheets were purchased from Sigma 
Aldrich
® 
(Gillingham, Dorset, UK). The solvents methanol (MeOH), ethanol (EtOH) and acetonitrile (ACN) 
were purchased from Fisher Scientific (Loughborough, Leicestershire, UK). Dexamethasone (C22H29FO5, MW 
392.19) was purchased from TCI Europe (Belgium). 2, 4-dinitrophenylhydrazine (DNPH) was purchased 
from Alfa Aesar
® 
(Heysham, Lancashire, UK). 4-Dimethylamino-6-(4-methoxy-1-naphthyl)-1, 3, 5-triazine-2-





Mass spectra and images were acquired in positive ion mode on an Applied Biosystems/MDS Sciex hybrid 
quadrupole time-of-flight mass spectrometer (Q-Star Pulsar-i) with an orthogonal MALDI ion source (Applied 
Biosystems, Foster City, California, USA) and a high repetition Neodymium-doped yttrium vanadate (Nd: 
YVO4) laser (355nm, 5 KHz) (Elforlight Ltd, Daventry, Northamptonshire, UK). Image acquisition was 
performed at a spatial resolution of 150 µm × 150 µm in “Raster Image” mode; images were generated using 
the freely available Novartis Biomap 3.7.5.5 software (www.maldi-msi.org). 
 
2.4. Tissue preparation 
Frozen control rat lung tissue was sectioned using a Leica cryostat (Leica Microsystems, Wetzlar, Germany) 
to produce 12 µm thick sections, which were thaw mounted onto clean aluminium sheets.   
 
2.5. Derivatization of glucocorticoids using DNPH 
2.5.1. In-solution derivatization procedure 
The derivatization procedure involved the incubation of 10 μL of a test steroid (0.5 mg/mL in acetonitrile) and 
10 μL of the solution of the DNPH matrix (1 mg/mL in acetonitrile with 0.3 % hydrochloric acid) in a 0.5 mL 
micro-centrifuge tube at room temperature for 30 minutes.  
The derivatized steroids were then analysed using the Q-Star instrument operated in positive ion mode with an 
accumulation time of 0.73 seconds, declustering potential of 0, focusing potential of 20, second declustering 
potential of 15, collision gas (nitrogen) of 3 arbitrary units (the three potentials and collision gas parameters 
are the same for each experiment and will not be quoted again from this point) and the scanning duration of 1 
minute with a mass range of m/z 150-1000. 
 
2.5.2. On-tissue derivatization procedure 
Fluticasone proprionate standards (500, 100, 50, 25 and 5 ng/µL prepared in 70 % acetonitrile) were spotted 
(1 μL) onto a control rat lung tissue section in triplicate. Then 1 μL of a 4 mg/mL solution of DNPH in 50: 50 
acetonitrile: water (v/v) with 0.1 % TFA was applied onto the spotted areas (10 times per spot and allowed to 
dry between applications). 
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Using the Labcyte Portrait 630
TM
 reagent multispotter (Labcyte, California, USA) an acoustic reagent spotter 
which is described elsewhere [14], the reactive matrix (4 mg/mL solution of DNPH in 50: 50 acetonitrile: 
water (v/v) with 0.1 % TFA) was deposited onto the spotted lung tissue (20 cycles with 200 μm distance 
between spots). 
Imaging experiments were performed using the Q-Star instrument with the “Raster Image” mode set to the 
"slow" speed, the instrument was operated in positive ion mode with an accumulation time of 0.29 seconds, 
ion release delay of 67.1 (the width of the pulse of ions released by the collision cell into the TOF), ion release 
width of 29.1, duration of scanning of 2 minutes and a mass range of m/z 150-700 with enhancement of m/z 
500.2. 
 
2.6. Derivatization of glucocorticoids using DMNTH 
2.6.1. In-solution derivatization procedure 
The derivatization procedure involved the incubation of 10 μL of a test steroid (2 mg/mL in acetonitrile) and 
10 μL of the DMNTH matrix (5 mg/mL in 50: 50 acetonitrile: water (v/v) with 0.1 % TFA) in a 0.5 mL 
micro-centrifuge tube at room temperature for 48 hours. 
The derivatized steroids were analysed using the Q-Star instrument operated in positive ion mode with an 
accumulation time of 0.73 seconds, the scanning duration of 1 minute with a mass range of m/z 250-900. 
 
2.6.2. On-tissue derivatization procedure  
Fluticasone proprionate standards (2000, 1000, 500, 250, 100, 50, 20 and 10 ng/µL prepared in 70 % 
acetonitrile) were spotted (1 µL) onto a control rat lung tissue section. Using the Labcyte Portrait 630
TM
 
reagent multispotter, the reactive matrix (5 mg/mL solution of DMNTH in 50: 50 acetonitrile: water (v/v) with 
0.1 % TFA) was deposited onto the spotted lung tissue (25 cycles with 200 μm spot-to-spot distance).  
Once the spotted tissue section had been coated with the reactive matrix, it was placed onto a polystyrene 
block and placed into a glass chamber containing 50 % methanol. The chamber lid was sealed using parafilm 
and incubated at 37°C with 5 % carbon dioxide for 48 hours in a Heraeus, Heracell incubator in order to create 
a humid environment.  
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Following incubation the section was analysed using the Q-Star instrument with the “Raster Image” mode set 
to the "slow" speed, the instrument was operated in positive ion mode with an accumulation time of 0.49 
seconds, ion release delay of 84.5, ion release width of 36.6, duration of scanning was 3 minutes and a mass 
range of m/z 450-800 with enhancement of m/z 793.2. 
 
2.7. Data processing 
Mass spectra from Analyst were exported in the form of text files and imported into mMass, an open source 
mass spectrometry software used for mass spectral processing [15]. 
 
3. Results and Discussion 
3.1. MALDI-MS analysis of glucocorticoids  
To illustrate the challenge of analysing glucocorticoids with MALDI-MS, a solution (500 ng/µL) of 
fluticasone propionate was mixed with the matrix CHCA and spotted onto a MALDI target plate. The 
resulting MALDI-MS spectrum is displayed in Figure 1A.  This spectrum shows an abundance of CHCA 
matrix related peaks in the m/z range <500, the spectrum also shows the sodium adduct ([M+Na]
+
) of 
fluticasone propionate at m/z 523.2 to be slightly more intense than the protonated molecule at m/z 501.2. This 
may be due to increased stability of the sodiated species [16]. 
 
3.2. In-solution derivatization using DNPH 
The MALDI-MS spectrum obtained for fluticasone propionate following derivatization with DNPH and using 
DNPH alone as matrix is shown in Figure 1B. This spectrum shows species identified as arising from the 
radical cation; ([M]
+
) at m/z 500.1, the sodium adduct ([M+Na]
+
) at m/z 523.1 (the most abundant ion), the 
potassium adduct ([M+K]
+
) at m/z 539.1 and the protonated hydrazone derivative ([MD+H]
+
) of fluticasone 
propionate at m/z 681.1. The spectrum also shows the presence of the protonated reactive matrix ([M+H]
+
) at 
m/z 199.0.  The signals observed for fluticasone propionate are approximately ten times as intense following 
derivatization with DNPH compared to the "corresponding" signals in Figure 1A. The assignment of m/z 
500.1 as the radical cation [M
+.
] for fluticasone propionate was previously explained as arising due to the 
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electron withdrawing effects of the attached nitro groups [5]. In order to test that this assignment was correct 
and that m/z 500.1 did not arise simply from in source fragmentation of the protonated hydrazone derivative 
an MS/MS experiment was carried out.  Figure 1C shows a product ion scan of m/z 681.3, as can be seen there 
is no evidence of m/z 500.1 in this spectrum suggesting that this is not a preferred pathway for the dissociation 
and hence fragmentation of the hydrazone derivative and supports the identification of m/z 500.1 as arising 
from the radical cation.  
 
During the analysis of DNPH derivatized budesonide and dexamethasone, the presence of a strong sodium 
adduct ion signal [M+Na]
+
 in addition to ions corresponding to the radical cation and protonated hydrazone 
derivative were observed. This has been previously reported [5]. Additionally the intensity of the sodium 
adduct was reported to be higher than that of the radical cation, this was also observed in the work reported 
here, as shown in Figure 1B. The ratio between the sodium adduct and the radical cation observed in Figure 
1B, could possibly be due to laser desorption ionization of unreacted fluticasone propionate due to the use of 
higher laser energies.  
In contrast to previous work where negative ion mode is used for the analysis of DNPH derivatized aldehydes 
and ketones [17], here the analysis of DNPH derivatized corticosteroids was found to give a better response in 
positive ion mode. To confirm this DNPH dertivatized fluticasone propionate was analysed in negative ion 
mode (data not shown), the spectrum did not show the presence of a deprotonated hydrazine derivative or 
related peaks. This was also observed in previous work [5]. Also of note, even though the analyzed 
corticosteroids contain two or more carbonyl functionalities, due to the steric accessibility only mono 
substituted hydrazone derivatives ([MD+H]
+
) were observed. 
 
One of the issues with the use of DNPH as a matrix is the crystallisation pattern, DNPH crystallises in long 
needles that does not properly cover the surface of the sample. It has previously been shown that a mixture of 
DNPH and CHCA in equal proportions maintains the reactive function of DNPH, whilst the CHCA promotes 
an even crystal coverage [7]. In order to determine if this could further improve the sensitivity and detection 
of the derivatized steroids a 1:1 mixture of CHCA and DNPH was employed. The MALDI-MS spectrum of 
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fluticasone propionate following derivatization with DNPH and subsequent analysis with CHCA as matrix is 
shown in Figure 1D. This MALDI-MS spectrum shows the radical cation ([M]
+
) at m/z 500.1 (the most 
abundant ion), the sodium adduct ([M+Na]
+
) at m/z 523.1, the potassium adduct ([M+K]
+
) at m/z 539.1 and 
the protonated hydrazone derivative ([MD+H]
+
) of fluticasone propionate at m/z 681.1. The spectrum also 
shows a high abundance of CHCA related adduct ions in the m/z range <500. The addition of CHCA to the 
DNPH has changed the ratio between the radical cation ([M]
+
) at m/z 500.1 and sodium adduct ([M+Na]
+
) at 
m/z 523.1 of fluticasone propionate. Also the spectrum shows the addition of CHCA as MALDI matrix 
appears to improve the intensity of the radical cation and the protonated hydrazone derivative ion by 
approximately a factor of 2 compared to the use of DNPH alone. 
 
3.3. In-solution derivatization using DMNTH 
The MALDI-MS spectrum obtained for fluticasone propionate following derivatization with DMNTH is 
shown in Figure 2A. The spectrum shows an abundant ion at m/z 793.3 which corresponds to the protonated 
hydrazone derivative ([MD+H]
+
) of fluticasone propionate. Also present is the protonated un-reacted DMNTH 
([M+H]
+
) ion at m/z 311.2. 
 
Derivatizing fluticasone proprionate DMNTH and subsequent analysis with CHCA as matrix gave a more 
complex spectrum (Figure 2B). This spectrum shows the protonated hydrazone derivative ([MD+H]
+
) at m/z 
793.3 of fluticasone propionate. The spectrum also shows the presence of protonated un-reacted DMNTH 
([M+H]
+
) at m/z 311.1 which is the most abundant peak. The use of CHCA improves the intensity of the 
protonated hydrazone derivative signal at m/z 793.3 by approximately a factor of 10. 
 
3.4. On-tissue derivatization using DNPH  
Following the successful application of DNPH and DMNTH for the in-solution derivatization of the range of 
glucocorticoids, the next step was to apply these reagents for on-tissue derivatization experiments. The 
MALDI-MS images shown in Figure 3 demonstrate the application of the reactive matrix DNPH for the 
derivatization of fluticasone propionate on a control rat lung tissue section. 
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The MALDI-MS images displayed in Figure 3 shows the distribution of the radical cation ([M]
+·
) m/z 500.2 
and the protonated hydrazone derivative ([MD+H]
+
) m/z 681.2 of fluticasone propionate within the spotted 
areas of the lung tissue. However, the lack of linearity of the response with respect to concentration needs to 
be investigated further. The cause may be related to the compound spiking methods and/ or matrix application. 
 
3.5. On-tissue derivatization using DMNTH 
The MALDI-MS images displayed in Figure 4 show the application of the reactive matrix DMNTH for the 
derivatization of fluticasone propionate on a control rat lung tissue section without incubation prior to 
analysis.  These images show the distribution of the protonated hydrazone derivative ([MD+H]
+
) at m/z 793.2, 
the distribution of the reactive matrix related peak at m/z 589.2 and the protonated hydrazone derivative 
([MD+H]
+
) at m/z 793.2 following normalisation with the reactive matrix peak at m/z 589.2. The distribution 
of the protonated hydrazone derivative ([MD+H]
+
) at m/z 793.2 is within the spotted areas of the tissue and the 
normalised image shows that it is detectable down to 500 ng/µL even without  an  incubation period. 
 
Figure 5 shows data obtained from the same experiment but with the addition of a 48 hour, 37 °C incubation 
period. The rationale for the inclusion of the incubation period was to attempt to increase the yield of 
derivatized product, by placing the sample in a humid environment the derivatisation reagent is kept in a 
liquid state on the surface of the spotted tissue section thereby maintaining the reaction between the 
corticosteroid and the derivatisation reagent. The increased reaction time is required due to the steric 
accessibility of the carbonyl functionalities. The MALDI-MS images shown in Figure 5 shows the distribution 
of the protonated hydrazone derivative ([MD+H]
+
) at m/z 793.2, the distribution of the reactive matrix related 
peak at m/z 589.2 and the protonated hydrazone derivative ([MD+H]
+
) at m/z 793.2 following normalisation 
with the reactive matrix peak at m/z 589.2. The distribution of the protonated hydrazone derivative ([MD+H]
+
) 
at m/z 793.2 is within the spotted areas of the tissue and the normalised image shows that it is detectable down 
to 50 ng/µL following a 48 hour incubation at 37 °C. Hence incubation of DMNTH coated samples at 37°C 
for 48 hours appeared to improve the detection of the protonated hydrazone derivative by a factor of 10. No 
visible evidence of tissue degradation was observed for this duration and temperature. 
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Some preliminary data obtained from the application of this methodology to other corticosteroids is shown in 
Figure 6. Here derivatization of fluticasone propionate, beclomethasone dipropionate, budesonide and 
dexamethasone on a control rat lung tissue section has been carried out. As previously described the DMNTH 
coated tissue section was incubated at 37 °C for 48 hours (prior to analysis). These data show the distribution 
of the protonated hydrazone derivatives ([MD+H]
+
) of the four steroids on-tissue for; fluticasone propionate at 
m/z 793.2, for beclomethasone dipropionate at m/z 813.2, for budesonide at m/z 723.2 and for dexamethasone 
at m/z 685.2. As can be seen signals for each corticosteroid as its hydrazone derivative were observed within 
the respective spotted areas of the tissue. These data indicate that DMNTH is capable of derivatizing a number 
of corticosteroids on-tissue and that this is a methodology worthy of further study. 
 
Conclusions 
The use of hydrazine based reagents has successfully been employed for the derivatization of glucocorticoids 
to form their respective hydrazones (both in-solution and on-tissue) and thus improve their mass spectral 
ionisation efficiency and detection. The application of DNPH to the on-tissue experiments was also 




and the protonated hydrazone derivative ([MD+H]
+
) of 
fluticasone propionate was observed in the spotted areas of the tissue sections. However further studies are 
required for the application of DNPH to on-tissue experiments to explain the apparent lack of linearity for the 
response with respect to concentration spotted onto the tissue section. 
The “tailor-made” reactive matrix DMNTH has successfully been applied to the in-solution derivatization of 
glucocorticoids. The application of DMNTH to on-tissue experiments has also been successful, it has been 
shown that analysis of samples immediately after reactive matrix application results in the detection of the 
protonated hydrazone derivative ([MD+H]
+
) of fluticasone propionate at a concentration of 500 ng/µL. It has 
been shown that a prolonged reaction (~48 hours) improves the detection of the protonated hydrazone 
derivative. It was found that following incubation in a humid environment (37°C) results in the detection of 
the protonated hydrazone derivative ([MD+H]
+
) of fluticasone propionate at a concentration of 50 ng/µL.  
Further improvements in sensitivity and limits of detection were observed when CHCA was added to the 
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Figure 1: A) MALDI-MS spectrum showing fluticasone propionate (500 ng/µL) mixed with the matrix 
CHCA. B) MALDI-MS spectrum showing fluticasone propionate (500 ng/µL) following 1 hour reaction with 
the reactive matrix DNPH at room temperature. C) MALDI-MS/MS spectrum of m/z 681.3 the protonated 
hydrazone derivative ([MD+H]
+
) of fluticasone proprionate. D) MALDI-MS spectrum showing fluticasone 
propionate (500 ng/µL) following 1 hour reaction with a mixture of the reactive matrix DNPH and CHCA at 
room temperature.  
Figure 2: A) MALDI-MS spectrum showing fluticasone priopionate (500 ng/µL) following 48 hour reaction 
with the reactive matrix DMNTH at room temperature.. B) MALDI-MS spectrum showing fluticasone 
priopionate (500 ng/µL) following 48 hour reaction with a mixture of the reactive matrix DMNTH and CHCA 
at room temperature.  
Figure 3: Optical images showing the spotted tissue section A) before and B) after reactive matrix deposition. 
MALDI-MS images showing the distribution of C) the radical cation ([M]
+·
) of fluticasone propionate at m/z 
500.2 and D) the protonated hydrazone derivative ([MD+H]
+
) of fluticasone propionate at m/z 681.2. 
Figure 4: Optical images showing the spotted tissue section A) before and B) after reactive matrix deposition. 
MALDI-MS images showing the distribution of the protonated hydrazone derivative of fluticasone propionate 
at m/z 793.2 C) before and D) after normalisation against the distribution of E) a reactive matrix related peak 
at m/z 589.2. 
Figure 5: Optical images showing the spotted tissue section A) before and B) after reactive matrix deposition. 
MALDI-MS images showing the distribution of the protonated hydrazone derivative of fluticasone propionate 
at m/z 793.2 C) before and D) after normalisation against the distribution of E) a reactive matrix related peak 
at m/z 589.2. 
Figure 6: Optical images showing the spotted tissue section A) before and B) after reactive matrix deposition. 
MALDI-MS images showing the distribution of the protonated hydrazone derivatives of C) fluticasone 
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propionate at m/z 793.2, D) beclomethasone dipropionate at m/z 813.2, E) budesonide at m/z 723.2, F) 
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